UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 10, 2019
ARCUS BIOSCIENCES, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware | | 001-38419 | | 47-3898435 |
(State or other jurisdiction of incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
3928 Point Eden Way
Hayward, CA 94545
(Address of principal executive offices)
Registrant’s telephone number, including area code: (510) 694-6200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Titles of Each Class | | Trading Symbol(s) | | Name of Each Exchange on which Registered |
Common Stock, Par Value $0.0001 Per Share | | RCUS | | The New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company: ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On September 10, 2019, Bristol-Myers Squibb Company (“BMS”) and Celgene Corporation (“Celgene”) announced that Kristen Hege, MD would assume a senior role within BMS, contingent upon consummation of the pending merger between BMS and Celgene. Given the overlapping pipeline between Arcus Biosciences, Inc. (the “Company”) and BMS, BMS’s conflict policies prohibit Dr. Hege from remaining a member of the Company’s Board of Directors (“Board”) following the consummation of the merger, and Dr. Hege will therefore be required to tender her resignation as a director of the Company. Dr. Hege does not serve on any Board committees.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | ARCUS BIOSCIENCES, INC. |
| | | | |
Date: September 16, 2019 | | By: | | /s/ Carolyn Tang |
| | | | Carolyn Tang |
| | | | Corporate Secretary |
